Lexeo Therapeutics Income Statement (2022-2026) | LXEO

Income Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter) 0.53M
Operating items
Amortization - Intangibles (Quarter) -0.01M0.03M0.06M-0.22M0.04M
Research & Development (Quarter) 15.36M11.39M16.44M11.24M17.25M-44.92M15.74M16.56M23.42M18.37M17.17M14.72M15.70M15.70M
Selling, General & Administrative (Quarter) 2.65M3.81M2.85M2.74M3.03M6.76M7.55M6.99M8.12M9.02M16.63M15.97M5.95M6.91M6.63M
Restructuring Costs (Quarter) 4.89M3.96M4.34M11.80M12.56M12.24M2.87M9.32M4.71M
Other Operating Expenses (Quarter) 53.13M-4.89M-3.96M-4.34M-11.80M-12.56M-12.24M-2.87M6.89M-4.71M
Operating Expenses (Quarter) 18.01M15.20M19.29M13.97M20.27M14.97M23.29M23.55M31.54M27.38M33.80M30.69M21.65M23.12M22.33M
Operating Income (Quarter) -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M-23.29M-23.55M-31.54M57.71M-33.80M-30.69M-21.65M-23.12M-22.33M
EBIT (Quarter) -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M-23.29M-23.55M-31.54M57.71M-33.80M-30.69M-21.65M-23.12M-22.33M
Non-operating items
Non Operating Investment Income (Quarter) 0.05M0.04M-0.33M
Interest & Investment Income (Quarter) 0.46M0.68M0.69M0.59M0.49M1.10M1.65M2.35M2.09M1.47M1.19M1.27M1.46M2.21M2.11M
Other Non Operating Income (Quarter) -0.00M-0.00M0.00M-0.01M-0.01M-0.00M-0.00M-0.00M-0.01M-0.01M0.01M-0.00M
Non Operating Income (Quarter) 0.43M-0.61M-0.00M-0.00M0.17M-0.01M-0.01M-0.00M-0.00M-0.00M4.58M-0.01M2.20M-0.00M
Net income details
EBT (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-20.92M-20.20M
Profit After Tax (Quarter) -17.05M-14.60M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.00M-20.20M
Income from Continuing Operations (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-20.92M-20.20M
Consolidated Net Income (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-20.92M-20.20M
Income towards Parent Company (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-20.92M-20.20M
Net Income towards Common Stockholders (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-20.92M-20.20M
Additional items
EPS (Basic) (Quarter) -10.38-8.86-11.58-8.30-12.3619.84-0.77-0.64-0.89-0.78-0.99-0.60-0.33-0.14-0.25
EPS (Weighted Average and Diluted) (Quarter) -10.38-8.86-11.58-8.30-12.3619.84-0.77-0.64-0.89-0.78-0.99-0.60-0.33-0.14-0.25
Shares Outstanding (Weighted Average) (Quarter) 1.63M1.63M1.61M1.62M1.62M5.35M27.98M33.00M33.06M31.79M33.11M38.37M60.98M53.65M81.18M
Shares Outstanding (Diluted Average) (Quarter) 1.63M1.63M1.61M1.62M1.62M5.35M27.98M33.00M33.06M31.79M33.11M43.57M60.98M53.65M81.18M
EBITDA (Quarter) -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M-21.68M-21.24M-31.54M57.71M-32.61M-26.06M-21.65M-23.12M-20.53M
Interest Expenses (Quarter) 0.03M0.05M0.05M0.05M0.05M0.05M0.04M0.04M0.04M0.03M0.03M0.03M0.02M0.02M0.02M